 | • レポートコード：D0804-14977 • 出版社/出版日：GlobalInfoResearch / 2020年7月21日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、143ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、ブルトン型チロシンキナーゼ（BTK）阻害剤の世界市場を広く調査・分析し、今後の市場展望をまとめております。ブルトン型チロシンキナーゼ（BTK）阻害剤の種類別市場規模（不可逆抑制剤、可逆抑制剤）、用途別市場規模（慢性リンパ性白血病（cll）、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁帯リンパ腫、小リンパ球性リンパ腫、ウォルデンストロムマクログロブリン血症、その他の選択的B細胞悪性腫瘍、慢性移植片対宿主病、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Johnson & Johnson、AbbVie、Sunesis、AstraZeneca、Gilead Sciences、Roche、INNOCARE、Bristol- Myers Squibb、Takeda、Biogen、BeiGene、Eternity Bioscience、ACEA Biosciences、KBP Biosciences、Carna Biosciences、ArQule、Acerta Pharma、Hanmi Pharmaceutical、Celgene Corporation、Aptose Biosciences、Tolero、Loxo Oncology、Principia Biopharma、Pharmacyclics、Zhejiang DTRM Biopharma、Ono Pharmaceutical、LSK BioPharma、X-Rx、Merck ・地域別グローバル市場分析 2015年-2020年 ・ブルトン型チロシンキナーゼ（BTK）阻害剤の北米市場（アメリカ、カナダ、メキシコ） ・ブルトン型チロシンキナーゼ（BTK）阻害剤のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・ブルトン型チロシンキナーゼ（BTK）阻害剤のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・ブルトン型チロシンキナーゼ（BTK）阻害剤の南米市場（ブラジル、アルゼンチン） ・ブルトン型チロシンキナーゼ（BTK）阻害剤の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：不可逆抑制剤、可逆抑制剤 ・用途別分析：慢性リンパ性白血病（cll）、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁帯リンパ腫、小リンパ球性リンパ腫、ウォルデンストロムマクログロブリン血症、その他の選択的B細胞悪性腫瘍、慢性移植片対宿主病、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The Bruton’s Tyrosine Kinase (BTK) Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
The most likely (base case) scenario is that the global Bruton’s Tyrosine Kinase (BTK) Inhibitors sales will be xx in 2020 from Bruton’s Tyrosine Kinase (BTK) Inhibitors million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market size is expected to grow at xx% or more annually for the next five years.
This report also researches and evaluates the impact of Covid-19 outbreak on the Bruton’s Tyrosine Kinase (BTK) Inhibitors industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Bruton’s Tyrosine Kinase (BTK) Inhibitors and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).
Market segmentation
Bruton’s Tyrosine Kinase (BTK) Inhibitors market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Bruton’s Tyrosine Kinase (BTK) Inhibitors market has been segmented into:
Irreversible Inhibitor
Reversible Inhibitor
By Application, Bruton’s Tyrosine Kinase (BTK) Inhibitors has been segmented into:
Chronic Lymphocytic Leukemia (cll)
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Small Lymphocytic Lymphoma
Waldenstrom Macroglobulinemia
Other Selective B Cell Malignancies
Chronic Graft-versus-host Disease
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market presented in the report. This section sheds light on the sales growth of different regional and country-level Bruton’s Tyrosine Kinase (BTK) Inhibitors markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Bruton’s Tyrosine Kinase (BTK) Inhibitors market.
The report offers in-depth assessment of the growth and other aspects of the Bruton’s Tyrosine Kinase (BTK) Inhibitors market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Share Analysis
Bruton’s Tyrosine Kinase (BTK) Inhibitors competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Bruton’s Tyrosine Kinase (BTK) Inhibitors sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Bruton’s Tyrosine Kinase (BTK) Inhibitors sales, revenue and market share for each player covered in this report.
The major players covered in Bruton’s Tyrosine Kinase (BTK) Inhibitors are:
Johnson & Johnson
AbbVie
Sunesis
AstraZeneca
Gilead Sciences
Roche
INNOCARE
Bristol- Myers Squibb
Takeda
Biogen
BeiGene
Eternity Bioscience
ACEA Biosciences
KBP Biosciences
Carna Biosciences
ArQule
Acerta Pharma
Hanmi Pharmaceutical
Celgene Corporation
Aptose Biosciences
Tolero
Loxo Oncology
Principia Biopharma
Pharmacyclics
Zhejiang DTRM Biopharma
Ono Pharmaceutical
LSK BioPharma
X-Rx
Merck
1 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Overview
1.1 Product Overview and Scope of Bruton’s Tyrosine Kinase (BTK) Inhibitors
1.2 Classification of Bruton’s Tyrosine Kinase (BTK) Inhibitors by Type
1.2.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Type in 2019
1.2.3 Irreversible Inhibitor
1.2.4 Reversible Inhibitor
1.3 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market by Application
1.3.1 Overview: Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Chronic Lymphocytic Leukemia (cll)
1.3.3 Follicular Lymphoma
1.3.4 Mantle Cell Lymphoma
1.3.5 Marginal Zone Lymphoma
1.3.6 Small Lymphocytic Lymphoma
1.3.7 Waldenstrom Macroglobulinemia
1.3.8 Other Selective B Cell Malignancies
1.3.9 Chronic Graft-versus-host Disease
1.3.10 Other
1.4 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market by Regions
1.4.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Bruton’s Tyrosine Kinase (BTK) Inhibitors (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Bruton’s Tyrosine Kinase (BTK) Inhibitors Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Bruton’s Tyrosine Kinase (BTK) Inhibitors Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Bruton’s Tyrosine Kinase (BTK) Inhibitors Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Bruton’s Tyrosine Kinase (BTK) Inhibitors Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Bruton’s Tyrosine Kinase (BTK) Inhibitors Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Bruton’s Tyrosine Kinase (BTK) Inhibitors Industry Impact
1.5.1 COVID-19 Potential Implications for the Bruton’s Tyrosine Kinase (BTK) Inhibitors
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Bruton’s Tyrosine Kinase (BTK) Inhibitors
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Johnson & Johnson
2.1.1 Johnson & Johnson Details
2.1.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Johnson & Johnson SWOT Analysis
2.1.4 Johnson & Johnson Product and Services
2.1.5 Johnson & Johnson Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.2 AbbVie
2.2.1 AbbVie Details
2.2.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 AbbVie SWOT Analysis
2.2.4 AbbVie Product and Services
2.2.5 AbbVie Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sunesis
2.3.1 Sunesis Details
2.3.2 Sunesis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sunesis SWOT Analysis
2.3.4 Sunesis Product and Services
2.3.5 Sunesis Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.4 AstraZeneca
2.4.1 AstraZeneca Details
2.4.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 AstraZeneca SWOT Analysis
2.4.4 AstraZeneca Product and Services
2.4.5 AstraZeneca Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.5 Gilead Sciences
2.5.1 Gilead Sciences Details
2.5.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Gilead Sciences SWOT Analysis
2.5.4 Gilead Sciences Product and Services
2.5.5 Gilead Sciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Roche SWOT Analysis
2.6.4 Roche Product and Services
2.6.5 Roche Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.7 INNOCARE
2.7.1 INNOCARE Details
2.7.2 INNOCARE Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 INNOCARE SWOT Analysis
2.7.4 INNOCARE Product and Services
2.7.5 INNOCARE Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bristol- Myers Squibb
2.8.1 Bristol- Myers Squibb Details
2.8.2 Bristol- Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bristol- Myers Squibb SWOT Analysis
2.8.4 Bristol- Myers Squibb Product and Services
2.8.5 Bristol- Myers Squibb Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Takeda SWOT Analysis
2.9.4 Takeda Product and Services
2.9.5 Takeda Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.10 Biogen
2.10.1 Biogen Details
2.10.2 Biogen Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Biogen SWOT Analysis
2.10.4 Biogen Product and Services
2.10.5 Biogen Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.11 BeiGene
2.11.1 BeiGene Details
2.11.2 BeiGene Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 BeiGene SWOT Analysis
2.11.4 BeiGene Product and Services
2.11.5 BeiGene Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.12 Eternity Bioscience
2.12.1 Eternity Bioscience Details
2.12.2 Eternity Bioscience Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Eternity Bioscience SWOT Analysis
2.12.4 Eternity Bioscience Product and Services
2.12.5 Eternity Bioscience Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.13 ACEA Biosciences
2.13.1 ACEA Biosciences Details
2.13.2 ACEA Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 ACEA Biosciences SWOT Analysis
2.13.4 ACEA Biosciences Product and Services
2.13.5 ACEA Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.14 KBP Biosciences
2.14.1 KBP Biosciences Details
2.14.2 KBP Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 KBP Biosciences SWOT Analysis
2.14.4 KBP Biosciences Product and Services
2.14.5 KBP Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.15 Carna Biosciences
2.15.1 Carna Biosciences Details
2.15.2 Carna Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Carna Biosciences SWOT Analysis
2.15.4 Carna Biosciences Product and Services
2.15.5 Carna Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.16 ArQule
2.16.1 ArQule Details
2.16.2 ArQule Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 ArQule SWOT Analysis
2.16.4 ArQule Product and Services
2.16.5 ArQule Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.17 Acerta Pharma
2.17.1 Acerta Pharma Details
2.17.2 Acerta Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Acerta Pharma SWOT Analysis
2.17.4 Acerta Pharma Product and Services
2.17.5 Acerta Pharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.18 Hanmi Pharmaceutical
2.18.1 Hanmi Pharmaceutical Details
2.18.2 Hanmi Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Hanmi Pharmaceutical SWOT Analysis
2.18.4 Hanmi Pharmaceutical Product and Services
2.18.3 Hanmi Pharmaceutical Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.19 Celgene Corporation
2.19.1 Celgene Corporation Details
2.19.2 Celgene Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Celgene Corporation SWOT Analysis
2.19.4 Celgene Corporation Product and Services
2.19.5 Celgene Corporation Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.20 Aptose Biosciences
2.20.1 Aptose Biosciences Details
2.20.2 Aptose Biosciences Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Aptose Biosciences SWOT Analysis
2.20.4 Aptose Biosciences Product and Services
2.20.5 Aptose Biosciences Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.21 Tolero
2.21.1 Tolero Details
2.21.2 Tolero Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Tolero SWOT Analysis
2.21.4 Tolero Product and Services
2.21.5 Tolero Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.22 Loxo Oncology
2.22.1 Loxo Oncology Details
2.22.2 Loxo Oncology Major Business and Total Revenue (Financial Highlights) Analysis
2.22.3 Loxo Oncology SWOT Analysis
2.22.4 Loxo Oncology Product and Services
2.22.5 Loxo Oncology Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.23 Principia Biopharma
2.23.1 Principia Biopharma Details
2.23.2 Principia Biopharma Major Business and Total Revenue (Financial Highlights) Analysis
2.23.3 Principia Biopharma SWOT Analysis
2.23.4 Principia Biopharma Product and Services
2.23.5 Principia Biopharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.24 Pharmacyclics
2.24.1 Pharmacyclics Details
2.24.2 Pharmacyclics Major Business and Total Revenue (Financial Highlights) Analysis
2.24.3 Pharmacyclics SWOT Analysis
2.24.4 Pharmacyclics Product and Services
2.24.5 Pharmacyclics Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.25 Zhejiang DTRM Biopharma
2.25.1 Zhejiang DTRM Biopharma Details
2.25.2 Zhejiang DTRM Biopharma Major Business and Total Revenue (Financial Highlights) Analysis
2.25.3 Zhejiang DTRM Biopharma SWOT Analysis
2.25.4 Zhejiang DTRM Biopharma Product and Services
2.25.5 Zhejiang DTRM Biopharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.26 Ono Pharmaceutical
2.26.1 Ono Pharmaceutical Details
2.26.2 Ono Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.26.3 Ono Pharmaceutical SWOT Analysis
2.26.4 Ono Pharmaceutical Product and Services
2.26.5 Ono Pharmaceutical Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.27 LSK BioPharma
2.27.1 LSK BioPharma Details
2.27.2 LSK BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.27.3 LSK BioPharma SWOT Analysis
2.27.4 LSK BioPharma Product and Services
2.27.5 LSK BioPharma Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.28 X-Rx
2.28.1 X-Rx Details
2.28.2 X-Rx Major Business and Total Revenue (Financial Highlights) Analysis
2.28.3 X-Rx SWOT Analysis
2.28.4 X-Rx Product and Services
2.28.5 X-Rx Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
2.29 Merck
2.29.1 Merck Details
2.29.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.29.3 Merck SWOT Analysis
2.29.4 Merck Product and Services
2.29.5 Merck Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Bruton’s Tyrosine Kinase (BTK) Inhibitors Players Market Share
3.2.2 Top 10 Bruton’s Tyrosine Kinase (BTK) Inhibitors Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Market Share by Regions
4.2 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
4.3 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
4.5 South America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
5 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries
5.1 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
5.2 USA Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
5.3 Canada Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
5.4 Mexico Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
6 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries
6.1 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
6.2 Germany Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
6.3 UK Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
6.4 France Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
6.5 Russia Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
6.6 Italy Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries
7.1 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
7.2 China Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
7.3 Japan Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
7.4 Korea Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
7.5 India Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
8 South America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries
8.1 South America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
8.2 Brazil Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
8.3 Argentina Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Bruton’s Tyrosine Kinase (BTK) Inhibitors by Countries
9.1 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
9.2 Saudi Arabia Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
9.3 UAE Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
9.4 Egypt Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
9.5 South Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue and Market Share by Type (2015-2020)
10.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Forecast by Type (2019-2024)
10.3 Irreversible Inhibitor Revenue Growth Rate (2015-2025)
10.4 Reversible Inhibitor Revenue Growth Rate (2015-2025)
11 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Segment by Application
11.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Application (2015-2020)
11.2 Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Forecast by Application (2019-2024)
11.3 Chronic Lymphocytic Leukemia (cll) Revenue Growth (2015-2020)
11.4 Follicular Lymphoma Revenue Growth (2015-2020)
11.5 Mantle Cell Lymphoma Revenue Growth (2015-2020)
11.6 Marginal Zone Lymphoma Revenue Growth (2015-2020)
11.7 Small Lymphocytic Lymphoma Revenue Growth (2015-2020)
11.8 Waldenstrom Macroglobulinemia Revenue Growth (2015-2020)
11.9 Other Selective B Cell Malignancies Revenue Growth (2015-2020)
11.10 Chronic Graft-versus-host Disease Revenue Growth (2015-2020)
11.11 Other Revenue Growth (2015-2020)
12 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size Forecast (2021-2025)
12.1 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Size Forecast (2021-2025)
12.2 Global Bruton’s Tyrosine Kinase (BTK) Inhibitors Market Forecast by Regions (2021-2025)
12.3 North America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
12.4 Europe Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
12.6 South America Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Bruton’s Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Bruton's Tyrosine Kinase (BTK) Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Johnson & Johnson Corporate Information, Location and Competitors
Table 7. Johnson & Johnson Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 8. Johnson & Johnson Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 9. Johnson & Johnson SWOT Analysis
Table 10. Johnson & Johnson Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 11. Johnson & Johnson Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. AbbVie Corporate Information, Location and Competitors
Table 13. AbbVie Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 14. AbbVie Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2018-2019)
Table 15. AbbVie SWOT Analysis
Table 16. AbbVie Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 17. AbbVie Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. Sunesis Corporate Information, Location and Competitors
Table 19. Sunesis Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 20. Sunesis Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 21. Sunesis SWOT Analysis
Table 22. Sunesis Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 23. Sunesis Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. AstraZeneca Corporate Information, Location and Competitors
Table 25. AstraZeneca Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 26. AstraZeneca Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 27. AstraZeneca SWOT Analysis
Table 28. AstraZeneca Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 29. AstraZeneca Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Gilead Sciences Corporate Information, Location and Competitors
Table 31. Gilead Sciences Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 32. Gilead Sciences Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 33. Gilead Sciences SWOT Analysis
Table 34. Gilead Sciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 35. Gilead Sciences Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Roche Corporate Information, Location and Competitors
Table 37. Roche Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 38. Roche Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 39. Roche SWOT Analysis
Table 40. Roche Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 41. Roche Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. INNOCARE Corporate Information, Location and Competitors
Table 43. INNOCARE Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 44. INNOCARE Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 45. INNOCARE SWOT Analysis
Table 46. INNOCARE Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 47. INNOCARE Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 48. Bristol- Myers Squibb Corporate Information, Location and Competitors
Table 49. Bristol- Myers Squibb Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 50. Bristol- Myers Squibb Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 51. Bristol- Myers Squibb SWOT Analysis
Table 52. Bristol- Myers Squibb Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 53. Bristol- Myers Squibb Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 54. Takeda Corporate Information, Location and Competitors
Table 55. Takeda Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 56. Takeda Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 57. Takeda SWOT Analysis
Table 58. Takeda Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 59. Takeda Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 60. Biogen Corporate Information, Location and Competitors
Table 61. Biogen Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 62. Biogen Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 63. Biogen SWOT Analysis
Table 64. Biogen Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 65. Biogen Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 66. BeiGene Corporate Information, Location and Competitors
Table 67. BeiGene Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 68. BeiGene Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 69. BeiGene SWOT Analysis
Table 70. BeiGene Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 71. BeiGene Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 72. Eternity Bioscience Corporate Information, Location and Competitors
Table 73. Eternity Bioscience Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 74. Eternity Bioscience Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 75. Eternity Bioscience SWOT Analysis
Table 76. Eternity Bioscience Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 77. Eternity Bioscience Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 78. ACEA Biosciences Corporate Information, Location and Competitors
Table 79. ACEA Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 80. ACEA Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 81. ACEA Biosciences SWOT Analysis
Table 82. ACEA Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 83. ACEA Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 84. KBP Biosciences Corporate Information, Location and Competitors
Table 85. KBP Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 86. KBP Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 87. KBP Biosciences SWOT Analysis
Table 88. KBP Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 89. KBP Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 90. Carna Biosciences Corporate Information, Location and Competitors
Table 91. Carna Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 92. Carna Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 93. Carna Biosciences SWOT Analysis
Table 94. Carna Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 95. Carna Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 96. ArQule Corporate Information, Location and Competitors
Table 97. ArQule Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 98. ArQule Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 99. ArQule SWOT Analysis
Table 100. ArQule Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 101. ArQule Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 102. Acerta Pharma Corporate Information, Location and Competitors
Table 103. Acerta Pharma Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 104. Acerta Pharma Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 105. Acerta Pharma SWOT Analysis
Table 106. Acerta Pharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 107. Acerta Pharma Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 108. Hanmi Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Type and Application
Table 109. Hanmi Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 110. Hanmi Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 111. Hanmi Pharmaceutical SWOT Analysis
Table 112. Hanmi Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 113. Hanmi Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 114. Celgene Corporation Corporate Information, Location and Competitors
Table 115. Celgene Corporation Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 116. Celgene Corporation Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 117. Celgene Corporation SWOT Analysis
Table 118. Celgene Corporation Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 119. Celgene Corporation Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 120. Aptose Biosciences Corporate Information, Location and Competitors
Table 121. Aptose Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 122. Aptose Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 123. Aptose Biosciences SWOT Analysis
Table 124. Aptose Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 125. Aptose Biosciences Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 126. Tolero Corporate Information, Location and Competitors
Table 127. Tolero Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 128. Tolero Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 129. Tolero SWOT Analysis
Table 130. Tolero Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 131. Tolero Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 132. Loxo Oncology Corporate Information, Location and Competitors
Table 133. Loxo Oncology Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 134. Loxo Oncology Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 135. Loxo Oncology SWOT Analysis
Table 136. Loxo Oncology Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 137. Loxo Oncology Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 138. Principia Biopharma Corporate Information, Location and Competitors
Table 139. Principia Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 140. Principia Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 141. Principia Biopharma SWOT Analysis
Table 142. Principia Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 143. Principia Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 144. Pharmacyclics Corporate Information, Location and Competitors
Table 145. Pharmacyclics Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 146. Pharmacyclics Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 147. Pharmacyclics SWOT Analysis
Table 148. Pharmacyclics Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 149. Pharmacyclics Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 150. Zhejiang DTRM Biopharma Corporate Information, Location and Competitors
Table 151. Zhejiang DTRM Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 152. Zhejiang DTRM Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 153. Zhejiang DTRM Biopharma SWOT Analysis
Table 154. Zhejiang DTRM Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 155. Zhejiang DTRM Biopharma Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 156. Ono Pharmaceutical Corporate Information, Location and Competitors
Table 157. Ono Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 158. Ono Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 159. Ono Pharmaceutical SWOT Analysis
Table 160. Ono Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 161. Ono Pharmaceutical Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 162. LSK BioPharma Corporate Information, Location and Competitors
Table 163. LSK BioPharma Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 164. LSK BioPharma Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 165. LSK BioPharma SWOT Analysis
Table 166. LSK BioPharma Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 167. LSK BioPharma Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 168. X-Rx Corporate Information, Location and Competitors
Table 169. X-Rx Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 170. X-Rx Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 171. X-Rx SWOT Analysis
Table 172. X-Rx Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 173. X-Rx Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 174. Merck Corporate Information, Location and Competitors
Table 175. Merck Bruton's Tyrosine Kinase (BTK) Inhibitors Major Business
Table 176. Merck Bruton's Tyrosine Kinase (BTK) Inhibitors Total Revenue (USD Million) (2017-2018)
Table 177. Merck SWOT Analysis
Table 178. Merck Bruton's Tyrosine Kinase (BTK) Inhibitors Product and Solutions
Table 179. Merck Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 180. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) by Players (2015-2020)
Table 181. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Players (2015-2020)
Table 182. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) by Regions (2015-2020)
Table 183. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Regions (2015-2020)
Table 184. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
Table 185. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Table 186. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) by Countries (2015-2020)
Table 187. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) by Countries (2015-2020)
Table 188. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue by Countries (2015-2020)
Table 189. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Table 190. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) by Countries (2015-2020)
Table 191. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Table 192. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) by Type (2015-2020)
Table 193. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Type (2015-2020)
Table 194. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Forecast by Type (2021-2025)
Table 195. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue by Application (2015-2020)
Table 196. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Application (2015-2020)
Table 197. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Forecast by Application (2021-2025)
Table 198. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Bruton's Tyrosine Kinase (BTK) Inhibitors Picture
Figure 2. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Type in 2019
Figure 3. Irreversible Inhibitor Picture
Figure 4. Reversible Inhibitor Picture
Figure 5. Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Application in 2019
Figure 6. Chronic Lymphocytic Leukemia (cll) Picture
Figure 7. Follicular Lymphoma Picture
Figure 8. Mantle Cell Lymphoma Picture
Figure 9. Marginal Zone Lymphoma Picture
Figure 10. Small Lymphocytic Lymphoma Picture
Figure 11. Waldenstrom Macroglobulinemia Picture
Figure 12. Other Selective B Cell Malignancies Picture
Figure 13. Chronic Graft-versus-host Disease Picture
Figure 14. Other Picture
Figure 15. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share in 2019
Figure 24. Global Top 10 Players Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Regions (2015-2020)
Figure 28. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Regions in 2018
Figure 29. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 30. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 32. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 34. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 35. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries in 2019
Figure 36. USA Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 37. Canada Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 39. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries in 2019
Figure 41. Germany Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 42. UK Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 43. France Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 44. Russia Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 45. Italy Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries in 2019
Figure 48. China Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 49. Japan Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 50. Korea Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 51. India Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 53. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 54. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries in 2019
Figure 55. Brazil Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 60. UAE Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue and Growth Rate (2015-2020)
Figure 63. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Type (2015-2020)
Figure 64. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Type in 2019
Figure 65. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share Forecast by Type (2021-2025)
Figure 66. Global Irreversible Inhibitor Revenue Growth Rate (2015-2020)
Figure 67. Global Reversible Inhibitor Revenue Growth Rate (2015-2020)
Figure 68. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Application (2015-2020)
Figure 69. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Share by Application in 2019
Figure 70. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Market Share Forecast by Application (2021-2025)
Figure 71. Global Chronic Lymphocytic Leukemia (cll) Revenue Growth Rate (2015-2020)
Figure 72. Global Follicular Lymphoma Revenue Growth Rate (2015-2020)
Figure 73. Global Mantle Cell Lymphoma Revenue Growth Rate (2015-2020)
Figure 74. Global Marginal Zone Lymphoma Revenue Growth Rate (2015-2020)
Figure 75. Global Small Lymphocytic Lymphoma Revenue Growth Rate (2015-2020)
Figure 76. Global Waldenstrom Macroglobulinemia Revenue Growth Rate (2015-2020)
Figure 77. Global Other Selective B Cell Malignancies Revenue Growth Rate (2015-2020)
Figure 78. Global Chronic Graft-versus-host Disease Revenue Growth Rate (2015-2020)
Figure 79. Global Other Revenue Growth Rate (2015-2020)
Figure 80. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
Figure 84. Europe Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
Figure 86. South America Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Bruton's Tyrosine Kinase (BTK) Inhibitors Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
ブルトン型チロシンキナーゼ（BTK）阻害剤の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The Bruton Tyrosine Kinase (BTK) Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value c…- VEGF阻害薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The VEGF Inhibitor Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …
- VEGF / VEGFR阻害薬の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The VEGF/VEGFR Inhibitor Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimiza…
- クレアチンキナーゼ試薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Creatine Kinase Reagent market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Creatine Kinase Reage…
- クレアチンキナーゼ試薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Creatine Kinase Reagent market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Creatine Kinase Reage…